Sheets Smith Wealth Management Halozyme Therapeutics, Inc. Transaction History
Sheets Smith Wealth Management
- $807 Million
- Q3 2024
A detailed history of Sheets Smith Wealth Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sheets Smith Wealth Management holds 6,840 shares of HALO stock, worth $414,709. This represents 0.05% of its overall portfolio holdings.
Number of Shares
6,840
Previous 6,848
0.12%
Holding current value
$414,709
Previous $358,000
9.22%
% of portfolio
0.05%
Previous 0.04%
Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
519Shares Held
124MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.07 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$781 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$353 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$245 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$225 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.45B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...